Literature DB >> 27172347

Batch- and Continuous-Flow Aerobic Oxidation of 14-Hydroxy Opioids to 1,3-Oxazolidines-A Concise Synthesis of Noroxymorphone.

Bernhard Gutmann1,2, Ulrich Weigl3, D Phillip Cox4, C Oliver Kappe5,6.   

Abstract

14-Hydroxymorphinone is converted to noroxymorphone, the immediate precursor of important opioid antagonists, such as naltrexone and naloxone, in a three-step reaction sequence. The initial oxidation of the N-methyl group in 14-hydroxymorphinone with in situ generated colloidal palladium(0) as the catalyst and molecular oxygen as the terminal oxidant constitutes the key transformation in this new route. This oxidation results in the formation of an unexpected oxazolidine ring structure. Subsequent hydrolysis of the oxazolidine under reduced pressure followed by hydrogenation in a packed-bed flow reactor using palladium(0) as the catalyst provides noroxymorphone in high purity and good overall yield. To overcome challenges associated with gas-liquid reactions with molecular oxygen, the key oxidation reaction was translated to a continuous-flow process.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  N-demethylation; aerobic oxidation; flow chemistry; naloxone; naltrexone

Mesh:

Substances:

Year:  2016        PMID: 27172347     DOI: 10.1002/chem.201601902

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  3 in total

Review 1.  N-Dealkylation of Amines.

Authors:  Ali Alipour Najmi; Rainer Bischoff; Hjalmar P Permentier
Journal:  Molecules       Date:  2022-05-20       Impact factor: 4.927

2.  Organophotocatalytic N-Demethylation of Oxycodone Using Molecular Oxygen.

Authors:  Yuesu Chen; Gabriel Glotz; David Cantillo; C Oliver Kappe
Journal:  Chemistry       Date:  2020-02-18       Impact factor: 5.236

3.  The Concept of Chemical Generators: On-Site On-Demand Production of Hazardous Reagents in Continuous Flow.

Authors:  Doris Dallinger; Bernhard Gutmann; C Oliver Kappe
Journal:  Acc Chem Res       Date:  2020-06-16       Impact factor: 22.384

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.